Walleye Capital LLC Sells 884 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Walleye Capital LLC reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) by 11.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,003 shares of the specialty pharmaceutical company’s stock after selling 884 shares during the quarter. Walleye Capital LLC’s holdings in Jazz Pharmaceuticals were worth $1,090,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Gateway Investment Advisers LLC raised its holdings in Jazz Pharmaceuticals by 0.4% in the 1st quarter. Gateway Investment Advisers LLC now owns 15,277 shares of the specialty pharmaceutical company’s stock valued at $2,378,000 after acquiring an additional 64 shares during the period. CWM LLC raised its holdings in Jazz Pharmaceuticals by 25.2% in the 1st quarter. CWM LLC now owns 422 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 85 shares during the period. Captrust Financial Advisors raised its holdings in Jazz Pharmaceuticals by 2.4% in the 1st quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock valued at $577,000 after acquiring an additional 86 shares during the period. Daiwa Securities Group Inc. raised its holdings in Jazz Pharmaceuticals by 3.1% in the 1st quarter. Daiwa Securities Group Inc. now owns 3,325 shares of the specialty pharmaceutical company’s stock valued at $518,000 after acquiring an additional 100 shares during the period. Finally, Trustcore Financial Services LLC raised its holdings in Jazz Pharmaceuticals by 47.7% in the 1st quarter. Trustcore Financial Services LLC now owns 347 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 112 shares during the period. 92.79% of the stock is owned by institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Samantha Pearce sold 8,508 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $155.00, for a total transaction of $1,318,740.00. Following the completion of the transaction, the senior vice president now directly owns 11,309 shares in the company, valued at $1,752,895. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Samantha Pearce sold 8,508 shares of the business’s stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $155.00, for a total transaction of $1,318,740.00. Following the transaction, the senior vice president now directly owns 11,309 shares in the company, valued at $1,752,895. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 2,142 shares of the business’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $160.06, for a total transaction of $342,848.52. Following the transaction, the chief accounting officer now owns 5,934 shares in the company, valued at $949,796.04. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,764 shares of company stock valued at $7,619,938. Corporate insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of analyst reports. UBS Group decreased their target price on shares of Jazz Pharmaceuticals from $194.00 to $191.00 and set a “buy” rating on the stock in a research report on Thursday, August 4th. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 9th. SVB Leerink increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an “outperform” rating in a research report on Thursday, August 4th. BMO Capital Markets increased their price target on shares of Jazz Pharmaceuticals from $185.00 to $188.00 and gave the stock an “outperform” rating in a research report on Thursday, August 4th. Finally, HC Wainwright cut their target price on shares of Jazz Pharmaceuticals from $210.00 to $204.00 in a research report on Friday, August 5th. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $203.69.

Jazz Pharmaceuticals Trading Down 3.1 %

JAZZ opened at $147.49 on Monday. Jazz Pharmaceuticals plc has a 1-year low of $117.64 and a 1-year high of $169.98. The company has a current ratio of 3.67, a quick ratio of 2.45 and a debt-to-equity ratio of 1.87. The company has a market cap of $9.21 billion, a P/E ratio of -173.52, a price-to-earnings-growth ratio of 1.24 and a beta of 0.68. The company has a fifty day moving average price of $155.29 and a two-hundred day moving average price of $155.04.

Jazz Pharmaceuticals Company Profile

(Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

See Also

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.